Product
OPT-302
Aliases
2.0 mg OPT-302
2 clinical trials
1 indication
Indication
Age-Related Macular DegenerationClinical trial
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMDStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMDStatus: Active (not recruiting), Estimated PCD: 2025-07-01